Details of a Researcher - ITAGAKI Shiro

ITAGAKI Shiro

写真a

Affiliation	Collaboration Center for Community and Industry
Job title	Special-Appoingment Associate Professor

To the head of this page.▲

Education 【 display / non-display 】

2003

　

　

Hokkaido University 薬学研究科医療薬学専攻博士課程中退
2001

　

　

Hokkaido University 薬学研究科医療薬学専攻修士課程修了
1999

　

　

Hokkaido University Faculty of Pharmaceutical Sciences 総合薬学科卒業

To the head of this page.▲

Degree 【 display / non-display 】

北海道大学博士（薬学）

To the head of this page.▲

Research Experience 【 display / non-display 】

2018.04

-

Now

Sapporo Medical University 特任准教授
2017.04

-

Now

Sapporo Medical University 産学連携コーディネーター

産学連携コーディネーター
2015.10

-

2017.03

Hirosaki University （教育研究院・医学系）准教授

准教授
2013.07

-

2017.03

Hirosaki University University Hospital 副センター長(兼務)

副センター長(兼務)
2010.04

-

2017.03

Hirosaki University University Hospital 副薬剤部長(併任)

副薬剤部長(併任)

display all >>

To the head of this page.▲

Professional Memberships 【 display / non-display 】

　

　

　

日本薬学会
　

　

　

medU－net

To the head of this page.▲

Research Areas 【 display / non-display 】

Humanities & social sciences Home economics, lifestyle science
Life sciences Clinical pharmacy
Life sciences Nutrition and health science
Life sciences Healthcare management, medical sociology

To the head of this page.▲

Research Interests 【 display / non-display 】

臨床試験
薬害
薬物動態学
transporter
産学連携

display all >>

To the head of this page.▲

Papers 【 display / non-display 】

A simple, dual direct expression plasmid system in prokaryotic and mammalian cells.

Manabu Murakami, Agnieszka M Murakami, Manabu Yonekura, Ichiro Miyoshi, Shirou Itagaki, Yasutaka Niwa

PNAS nexus 2 ( 5 ) pgad139 2023.05 [International journal]

　View Summary

We introduce a simple, dual direct cloning plasmid system (pgMAX-II) for gene expression analysis in both prokaryotic (Escherichia coli) and mammalian cells. This system, which uses a prokaryotic expression unit adapted from the pgMAX system and a mammalian promoter, is effective for subcloning using the DNA topoisomerase II toxin CcdB. Given that molecular biological cloning systems broadly rely on E. coli for rapid growth, the proposed concept may have wide applicability beyond mammalian cells.

DOI PubMed
Rapid method for plasmid DNA recombination (Murakami-system).

Agnieszka M Murakami, Manabu Yonekura, Katsuhiro Nagatomo, Yasutaka Niwa, Shirou Itagaki, Manabu Murakami

MethodsX 10 102167 - 102167 2023 [International journal]

　View Summary

DNA recombination is a useful technology for cloning and subsequent functional analysis, while standard techniques for plasmid DNA recombination have remained unchanged. In the present study, we introduced rapid method for plasmid DNA recombination, which we named "Murakami-system", to complete the experiments in under 33 h. For this purpose, we selected the following: PCR amplification with 25 cycles and E. coli strain with rapid growth (incubation time of 6-8 h). In addition, we selected rapid plasmid DNA purification (mini-prep; ∼10 min) and rapid restriction enzyme incubation (20 min). This recombination system enabled rapid plasmid DNA recombination within 24-33 h, which could be useful in various fields. We also established a 1-day method for competent cell preparation. Our rapid recombination system allowed several sessions of plasmid DNA recombination to be performed every week, which improves the functional analysis of various genes.•"Rapid method for plasmid DNA recombination (Murakami-system).•E. coli strain with rapid growth (incubation time of 6-8 h).•Combination of rapid protocols (PCR, electrophoresis, DNA purification, ligation, and mini-prep) enabled plasmid DNA recombination within 24-33 h.

DOI PubMed
Enhanced β-adrenergic response in mice with dominant-negative expression of the PKD2L1 channel

Manabu Murakami, Agnieszka M. Murakami, Takayuki Nemoto, Takayoshi Ohba, Manabu Yonekura, Yuichi Toyama, Hirofumi Tomita, Yasushi Matsuzaki, Daisuke Sawamura, Kazuyoshi Hirota, Shirou Itagaki, Yujiro Asada, Ichiro Miyoshi

PLOS ONE ( Public Library of Science (PLoS) ) 17 ( 1 ) e0261668 - e0261668 2022

　View Summary

Polycystic kidney disease (PKD) is the most common genetic cause of kidney failure in humans. Among the various PKD-related molecules, PKD2L1 forms cation channels, but its physiological importance is obscure. In the present study, we established a transgenic mouse line by overexpressing the dominant-negative form of the mouse PKD2L1 gene (i.e., lacking the pore-forming domain). The resulting PKD2L1del-Tg mice exhibited supraventricular premature contraction, as well as enhanced sensitivity to β-adrenergic stimulation and unstable R-R intervals in electrocardiography. During spontaneous atrial contraction, PKD2L1del-Tg atria showed enhanced sensitivity to isoproterenol, norepinephrine, and epinephrine. Action potential recording revealed a shortened action potential duration in PKD2L1del-Tg atria in response to isoproterenol. These findings indicated increased adrenergic sensitivity in PKD2L1del-Tg mice, suggesting that PKD2L1 is involved in sympathetic regulation.

DOI
Attenuated β-adrenergic response in calcium/calmodulin-dependent protein kinase IV-knockout mice.

Manabu Murakami, Agnieszka M Murakami, Yasushi Matsuzaki, Daisuke Sawamura, Takayoshi Ohba, Ichirou Miyoshi, Shirou Itagaki, Hiroyuki Sakagami

PloS one 16 ( 4 ) e0249932 2021 [Refereed] [International journal]

　View Summary

In the present study, we examined the importance of Ca2+/calmodulin-dependent protein kinase IV (CaMKIV) in the regulation of cardiac function using genetically modified CaMKIV-null mice. RT-PCR analysis revealed decreased expression of voltage-dependent calcium channels in the cardiac myocytes of CaMKIV-null mice compared with wild-type mice. CaMKIV-null mice showed shortened QT time on electrocardiograms. Pharmacological analysis revealed decreased responsiveness to the β-adrenergic blocker propranolol in CaMKIV-null mice, whereas the plasma norepinephrine level was not affected. CaMKIV-null mice showed decreased baroreflex on electrocardiograms. Heart rate variability analysis showed unstable R-R intervals, a decreased low frequency power/high frequency power (LF/HF) ratio, and increased standard deviation of the normal to normal R-R intervals (SDNN) in CaMKIV-null mice, suggesting decreased responsiveness to β-adrenergic stimulation in CaMKIV-null mice. Atrial contraction analysis and cardiac action potential recording showed a decreased response to the β-adrenoceptor agonist isoproterenol in CaMKIV-null mice. Furthermore, fluorescence imaging in a CRE-hrGFP assay revealed a decreased response to isoproterenol in CaMKIV-null cardiac myocytes. Taken together, our data strongly suggest a significant effect of CaMKIV gene ablation on cardiac β-adrenergic signal transduction.

DOI PubMed
Decreased cardiac pacemaking and attenuated β-adrenergic response in TRIC-A knockout mice.

Manabu Murakami, Yuichi Toyama, Manabu Yonekura, Takayoshi Ohba, Yasushi Matsuzaki, Daisuke Sawamura, Agnieszka M Murakami, Miyuki Nishi, Shirou Itagaki, Hirofumi Tomita, Hiroshi Takeshima

PloS one 15 ( 12 ) e0244254 2020 [Refereed] [International journal]

　View Summary

Changes in intracellular calcium levels in the sinus node modulate cardiac pacemaking (the calcium clock). Trimeric intracellular cation (TRIC) channels are counterion channels on the surface of the sarcoplasmic reticulum and compensate for calcium release from ryanodine receptors, which play a major role in calcium-induced calcium release (CICR) and the calcium clock. TRIC channels are expected to affect the calcium clock in the sinus node. However, their physiological importance in cardiac rhythm formation remains unclear. We evaluated the importance of TRIC channels on cardiac pacemaking using TRIC-A-null (TRIC-A-/-) as well as TRIC-B+/-mice. Although systolic blood pressure (SBP) was not significantly different between wild-type (WT), TRIC-B+/-, and TRIC-A-/-mice, heart rate (HR) was significantly lower in TRIC-A-/-mice than other lines. Interestingly, HR and SBP showed a positive correlation in WT and TRIC-B+/-mice, while no such correlation was observed in TRIC-A-/-mice, suggesting modification of the blood pressure regulatory system in these mice. Isoproterenol (0.3 mg/kg) increased the HR in WT mice (98.8 ± 15.1 bpm), whereas a decreased response in HR was observed in TRIC-A-/-mice (23.8 ± 5.8 bpm), suggesting decreased sympathetic responses in TRIC-A-/-mice. Electrocardiography revealed unstable R-R intervals in TRIC-A-/-mice. Furthermore, TRIC-A-/-mice sometimes showed sinus pauses, suggesting a significant role of TRIC-A channels in cardiac pacemaking. In isolated atrium contraction or action potential recording, TRIC-A-/-mice showed decreased response to a β-adrenergic sympathetic nerve agonist (isoproterenol, 100 nM), indicating decreased sympathetic responses. In summary, TRIC-A-/-mice showed decreased cardiac pacemaking in the sinus node and attenuated responses to β-adrenergic stimulation, indicating the involvement of TRIC-A channels in cardiac rhythm formation and decreased sympathetic responses.

DOI PubMed

display all >>

To the head of this page.▲

Books and Other Publications 【 display / non-display 】

大豆たん白質研究16

板垣史郎( Part： Contributor, アンジオテンシン変換酵素を標的とした大豆由来内臓脂肪型肥満症改善物質の探索)

2014.12
新薬展望2014

岡村祐嗣, 板垣史郎, 早狩誠( Part： Contributor, 第三部治療における最近の新薬の位置付け（薬効別）～新薬の広場～抗菌薬)

2014.01
臨床薬理の進歩2013

板垣史郎, 工藤正純, 新岡丈典, 小島佳也, 保嶋実, 早狩誠( Part： Contributor, 小児バンコマイシン投与設計支援時に用いられる血中濃度予測系の正確度と精度向上に関する検討)

2013.06
新薬展望2013

太田真帆, 板垣史郎, 早狩誠( Part： Contributor, 第三部治療における最近の新薬の位置付け（薬効別）～新薬の広場～睡眠薬・鎮静薬・抗不安薬)

2013.01
医薬ジャーナル2012年10月号

高橋志織, 岡村祐嗣, 小原信一, 板垣史郎, 早狩誠( Part： Contributor, 腎機能に基づいたレボフロキサシンの適正使用に向けた介入効果～処方監査支援システムの活用～)

2012.10

display all >>

To the head of this page.▲

Misc 【 display / non-display 】

28-P4AM-110 当院におけるClostridium difficile感染症治療の実態調査(感染制御(治療薬)2,一般演題(ポスター),新時代を拓く医療薬学フロンティア)

岡村祐嗣, 高橋志織, 津山博匡, 木村正彦, 板垣史郎, 萱場広之, 早狩誠

日本医療薬学会年会講演要旨集 ( 日本医療薬学会 ) 24 393 - 393 2014.08

CiNii
27-P4AM-212 弘前大学医学部附属病院における感染性心内膜炎の薬物治療の現状(感染制御(治療薬)1,一般演題(ポスター),新時代を拓く医療薬学フロンティア)

太田真帆, 岡村祐嗣, 板垣史郎, 萱場広之, 早狩誠

日本医療薬学会年会講演要旨集 ( 日本医療薬学会 ) 24 303 - 303 2014.08

CiNii
28-P4AM-103 放射線化学療法と結核菌熱水抽出物(アンサー注)との同時併用による骨髄抑制への影響(がん薬物療法(副作用対策)1,一般演題(ポスター),新時代を拓く医療薬学フロンティア)

細井一広, 中川潤一, 太田真帆, 阿保成慶, 川村広明, 照井一史, 板垣史郎, 早狩誠

日本医療薬学会年会講演要旨集 ( 日本医療薬学会 ) 24 392 - 392 2014.08

CiNii
土-P3-368 外来化学療法室における治療当日の患者指導有用性の検討(がん薬物療法(服薬指導・情報提供),ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

川村広明, 照井一史, 中川潤一, 小田桐奈央, 高橋志織, 阿保成慶, 板垣史郎, 早狩誠

日本医療薬学会年会講演要旨集 ( 日本医療薬学会 ) 23 313 - 313 2013.08

CiNii
P1-437 ARBの物理化学的特性に関する文献的考察を踏まえた高血圧治療剤としてのARBの総合的評価(医薬品情報・データベース,ポスター,一般演題,岐路に立つ医療〜千年紀の目覚め〜よみがえれ!ニッポン!薬の改革は我らが手で!)

板垣史郎, 野呂秀紀, 下山律子, 藤田祥子, 早狩誠

日本医療薬学会年会講演要旨集 ( 日本医療薬学会 ) 22 339 - 339 2012.10

CiNii

display all >>

To the head of this page.▲

Awards 【 display / non-display 】

日本薬学会北海道支部奨励賞

2008

To the head of this page.▲

Research Projects 【 display / non-display 】

DDSがアニサキス感染から身を守る: 萌芽から開拓への新展開

挑戦的研究(開拓)

Project Year :

2023

-

2025

丁野純男
血流感染症特異的治療薬の開発に向けた大規模スクリーニングとｖｉｖｏＥＦ阻害剤ライブラリーの構築

プロジェクト支援型（START）

Project Year :

2021

-

2023

佐藤豊孝
従来の抗菌薬開発法にとらわれない、新たな細菌感染症治療薬のスクリーニングに関する研究開発

Project Year :

2019

-

2021

佐藤豊孝

　View Summary

研究開発分担者 2019年12月6日札幌医科大学プレスリリース停滞していた抗菌薬開発に光明！これまでにない新たなスクリーニング法の構築がAMED令和元年度「創薬基盤推進研究事業」に採択されました https://web.sapmed.ac.jp/jp/news/photo/jmjbbn000000ky3l.html https://web.sapmed.ac.jp/jp/news/press/jmjbbn000000kxhc.html
アニサキス駆虫薬の探索とDDS創製：魚生食文化継承のため先人の研究挫折を超克する

Project Year :

2019

-

2020

丁野純男

　View Summary

研究分担者
病室不快臭の科学分析に基づく入院高齢者の生活環境改善に関する基礎研究

Project Year :

2018

　

　

板垣史郎

Authorship： Principal investigator